Edition:
United States

Reata Pharmaceuticals Inc (RETA.OQ)

RETA.OQ on NASDAQ Stock Exchange Global Market

64.49USD
11:44am EDT
Change (% chg)

$18.09 (+38.99%)
Prev Close
$46.40
Open
$51.00
Day's High
$64.58
Day's Low
$50.53
Volume
189,536
Avg. Vol
70,494
52-wk High
$64.58
52-wk Low
$19.32

Chart for

About

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical... (more)

Overall

Beta: --
Market Cap(Mil.): $1,215.09
Shares Outstanding(Mil.): 26.16
Dividend: --
Yield (%): --

Financials

  RETA.OQ Industry Sector
P/E (TTM): -- 217.69 33.34
EPS (TTM): -1.44 -- --
ROI: -59.61 -3.65 13.18
ROE: -- -5.62 15.09

BRIEF-Reata Pharmaceuticals Posts Q1 Earnings Per Share $0.16

* REATA PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS

May 08 2018

BRIEF-Reata Pharmaceuticals Announces New Preclinical Data Of Omaveloxolone

* REATA ANNOUNCES NEW PRECLINICAL DATA DEMONSTRATING THE POTENTIAL OF OMAVELOXOLONE IN THE TREATMENT OF FRIEDREICH’S ATAXIA AND OTHER SEVERE NEUROLOGICAL DISEASES Source text for Eikon: Further company coverage:

Apr 24 2018

BRIEF-Reata Provides Update On Phase 2 Portion Of Cardinal Study Of Bardoxolone Methyl In Patients With Alport Syndrome

* REATA PROVIDES UPDATE ON THE PHASE 2 PORTION OF THE CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME

Apr 11 2018

BRIEF-Reata Announces That Kyowa Hakko Kirin Received Sakigake Priority Review Designation For Bardoxolone Methyl In Japan

* REATA ANNOUNCES THAT KYOWA HAKKO KIRIN RECEIVED SAKIGAKE PRIORITY REVIEW DESIGNATION FOR BARDOXOLONE METHYL IN JAPAN Source text for Eikon: Further company coverage:

Mar 29 2018

BRIEF-Reata Announces Positive Top-Line Data For Treatment Of PH-ILD With Bardoxolone Methyl From Phase 2 Lariat Trial

* REATA ANNOUNCES POSITIVE TOP-LINE DATA FOR TREATMENT OF PH-ILD WITH BARDOXOLONE METHYL FROM THE PHASE 2 LARIAT TRIAL

Mar 22 2018

BRIEF-Reata Pharmaceuticals Inc. Announces Q4 Loss Per Share $0.64

* REATA PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS

Mar 02 2018

BRIEF-Reata Announces Top-Line Data From Study Of Patients With Mitochondrial Myopathies

* REATA ANNOUNCES TOP-LINE DATA FROM THE DOSE-ESCALATION COHORTS OF THE PHASE 2 MOTOR STUDY OF OMAVELOXOLONE IN PATIENTS WITH MITOCHONDRIAL MYOPATHIES Source text for Eikon: Further company coverage:

Mar 01 2018

BRIEF-Reata Provides Program Update On Phase 2 Rare Renal Clinical Trials

* REATA PROVIDES PROGRAM UPDATE ON PHASE 2 RARE RENAL CLINICAL TRIALS

Feb 27 2018

BRIEF-Reata Announces Improvements In Kidney Function With Bardoxolone Methyl Maintained For Two Years In Pah Patients From Lariat Trial

* REATA ANNOUNCES IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE METHYL MAINTAINED FOR TWO YEARS IN PAH PATIENTS FROM LARIAT TRIAL Source text for Eikon: Further company coverage:

Feb 12 2018

Earnings vs. Estimates